The Volpara Health Technologies Ltd (ASX: VHT) share price is climbing today following the release of the company’s quarterly report.
At the time of writing, the healthcare technology company’s shares are up 1.17% to $1.295.
How did Volpara perform for Q2 FY22?
According to its release, Volpara advised record sales and cash inflows for the 3 months ending 30 September.
In particular, cash receipts from customers totalled NZ$7.1 million (A$6.79 million), an increase of 11% on the previous quarter. Compared against the prior corresponding period, this metric grew 52% — or 68% in constant currency terms.
Subscription-based receipts continued to accelerate, representing more than NZ$6.9 million (A$6.60 million) for the 3 months. This is a jump of 63% year-on-year, or roughly 74% in constant currency.
Net operating cash outflow came to NZ$3.8 million (A$3.63 million), consistent with Q2 FY21. Some material supplier contract renewals, such as its annual insurance program, kept the costs in line.
Volpara noted that it closed the quarter with cash of NZ$25 million (AS23.91) on hand and no debt.
On the Software-as-a-Service (SaaS) front, annual recurring revenue (ARR) stood at US$20.4 million (A$27.24) million. Contracts were signed across the company’s full product suite as both standalone sales and platform deals. Many existing customers also increased contracts with Volpara whether by adding on products or expanding use of existing products.
The average revenue per user (ARPU) improved to US$1.46 (A$1.95), up 5% on the prior quarter. Its legacy MRS support contracts were heavily weighted towards the lower ARPU ranges, while its subscription-based products weighted more to the higher ARPUs.
Volpara group CEO Dr Ralph Highnam commented:
Q2 is traditionally our weakest quarter for sales, and yet today we’ve shown that we’ve had a record quarter not only for sales but also cash inflows.
…Our job now is to keep that momentum and passion for what we do as we go through the second half of the year, keeping in mind potential winter waves of COVID in the northern hemisphere.
Volpara share price summary
The past 12 months have been a disappointing run for investors, with the company’s shares down almost 11%. When looking at year-to-date, its losses are hovering around 9% over the period.
Based on today’s price, Volpara presides a market capitalisation of roughly $329 million and has approximately 251.3 million shares outstanding.
The post Volpara (ASX:VHT) share price pushes higher on record quarterly update appeared first on The Motley Fool Australia.
Should you invest $1,000 in Volpara right now?
Before you consider Volpara, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Volpara wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
More reading
- 2 small cap ASX shares with a lot of potential
- Volpara (ASX:VHT) share price charges higher on Q2 update
- Volpara (ASX:VHT) share price edges lower despite biggest contract win
- 2 ASX tech shares that might be buys in October 2021
- Top ASX shares to buy in October 2021
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool Australia owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/3baqLwF
Leave a Reply